Kevin A. Cassady

2.4k total citations
59 papers, 1.6k citations indexed

About

Kevin A. Cassady is a scholar working on Genetics, Epidemiology and Oncology. According to data from OpenAlex, Kevin A. Cassady has authored 59 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Genetics, 31 papers in Epidemiology and 26 papers in Oncology. Recurrent topics in Kevin A. Cassady's work include Virus-based gene therapy research (41 papers), Herpesvirus Infections and Treatments (29 papers) and CAR-T cell therapy research (24 papers). Kevin A. Cassady is often cited by papers focused on Virus-based gene therapy research (41 papers), Herpesvirus Infections and Treatments (29 papers) and CAR-T cell therapy research (24 papers). Kevin A. Cassady collaborates with scholars based in United States, Italy and South Korea. Kevin A. Cassady's co-authors include Martin Gross, James M. Markert, Bernard Roizman, G. Yancey Gillespie, Gregory K. Friedman, Mohammed G. Ghonime, R. J. Whitley, Jacqueline N. Parker, Paul M. Foreman and Timothy P. Cripe and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Kevin A. Cassady

56 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin A. Cassady United States 23 887 695 661 557 408 59 1.6k
Samita Andreansky United States 20 630 0.7× 449 0.6× 786 1.2× 515 0.9× 855 2.1× 34 1.8k
Eric Bartee United States 22 623 0.7× 616 0.9× 555 0.8× 774 1.4× 785 1.9× 49 2.0k
Gail Henderson United States 21 666 0.8× 307 0.4× 775 1.2× 722 1.3× 533 1.3× 28 1.7k
Suzanne Greiner United States 19 1.0k 1.1× 411 0.6× 549 0.8× 511 0.9× 173 0.4× 21 1.5k
Steven J. Werden United States 19 478 0.5× 574 0.8× 326 0.5× 813 1.5× 345 0.8× 23 1.6k
Karen J. Scott United Kingdom 20 628 0.7× 657 0.9× 123 0.2× 314 0.6× 427 1.0× 33 1.2k
Elena A. Kashentseva United States 23 1.7k 1.9× 938 1.3× 187 0.3× 1.5k 2.7× 239 0.6× 53 2.3k
Katherine L. Molnar-Kimber United States 27 1.1k 1.3× 577 0.8× 681 1.0× 886 1.6× 336 0.8× 37 2.1k
Louisa S. Chard United Kingdom 21 532 0.6× 508 0.7× 187 0.3× 714 1.3× 258 0.6× 39 1.5k
James C. Neil United Kingdom 26 715 0.8× 261 0.4× 536 0.8× 769 1.4× 512 1.3× 55 1.9k

Countries citing papers authored by Kevin A. Cassady

Since Specialization
Citations

This map shows the geographic impact of Kevin A. Cassady's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin A. Cassady with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin A. Cassady more than expected).

Fields of papers citing papers by Kevin A. Cassady

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin A. Cassady. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin A. Cassady. The network helps show where Kevin A. Cassady may publish in the future.

Co-authorship network of co-authors of Kevin A. Cassady

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin A. Cassady. A scholar is included among the top collaborators of Kevin A. Cassady based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin A. Cassady. Kevin A. Cassady is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saini, Uksha, et al.. (2025). Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models. Journal for ImmunoTherapy of Cancer. 13(7). e012227–e012227.
2.
Cassady, Kevin A., et al.. (2025). CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma. Mathematical Biosciences. 389. 109531–109531. 2 indexed citations
3.
Kelly, Michael C., et al.. (2025). Direct oHSV Infection Induces DC Maturation and a Tumor Therapeutic Response. Viruses. 17(8). 1134–1134.
4.
Luo, Wen, Hoang Hai, Hongwen Zhu, et al.. (2024). Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning “Two Keys” simultaneously. Journal of Experimental & Clinical Cancer Research. 43(1). 193–193. 6 indexed citations
5.
Chu, Yaya, Uksha Saini, M. Fevzi Özkaynak, et al.. (2024). Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma. SHILAP Revista de lepidopterología. 33(1). 200927–200927. 5 indexed citations
6.
Chen, Chun‐Yu, et al.. (2023). Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy. Molecular Therapy — Oncolytics. 29. 118–124. 12 indexed citations
7.
Brown, Christine E., Brenda Aguilar, Jamie R. Wagner, et al.. (2022). Abstract CT541A: Oncolytic viral reshaping of the tumor microenvironment to promote CAR T cell therapy for glioblastoma. Cancer Research. 82(12_Supplement). CT541A–CT541A. 1 indexed citations
8.
Pearl, Taylor M., James M. Markert, Kevin A. Cassady, & Mohammed G. Ghonime. (2019). Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Molecular Therapy — Oncolytics. 13. 14–21. 69 indexed citations
9.
Hutzen, Brian, Mohammed G. Ghonime, Elaine R. Mardis, et al.. (2019). Immunotherapeutic Challenges for Pediatric Cancers. Molecular Therapy — Oncolytics. 15. 38–48. 25 indexed citations
10.
Ghonime, Mohammed G. & Kevin A. Cassady. (2018). Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunology Research. 6(12). 1499–1510. 34 indexed citations
11.
Sprague, Leslee, et al.. (2018). Please Stand By: How Oncolytic Viruses Impact Bystander Cells. Future Virology. 13(9). 671–680. 6 indexed citations
12.
Erdem, Güliz, et al.. (2018). Clinical and Radiologic Manifestations of Bone Infection in Children with Cat Scratch Disease. The Journal of Pediatrics. 201. 274–280.e12. 10 indexed citations
13.
Jackson, Joshua, James M. Markert, Li Li, Steven L. Carroll, & Kevin A. Cassady. (2016). STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Molecular Cancer Research. 14(5). 482–492. 35 indexed citations
14.
Roth, Justin C., Kevin A. Cassady, James J. Cody, et al.. (2014). Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates. 776275620–776275620. 3 indexed citations
15.
16.
Roth, Justin C., Jennifer Coleman, Richard J. Whitley, et al.. (2014). Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Therapy. 21(11). 984–990. 18 indexed citations
17.
Friedman, Gregory K., et al.. (2013). Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. Frontiers in Oncology. 3. 28–28. 13 indexed citations
18.
Cassady, Kevin A. & Jacqueline N. Parker. (2010). Herpesvirus Vectors for Therapy of Brain Tumors~!2009-12-17~!2010-01-07~!2010-06-17~!. PubMed. 4(3). 103–108. 6 indexed citations
19.
Prichard, Mark N., Shannon L. Daily, Geraldine M. Jefferson, et al.. (2008). ACYCLOVIR-RESISTANT CHRONIC VERRUCOUS VACCINE STRAIN VARICELLA IN A PATIENT WITH NEUROBLASTOMA. The Pediatric Infectious Disease Journal. 27(10). 946–948. 17 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samita Andreansky Breakdown of academic impact, for papers by Eric Bartee Breakdown of academic impact, for papers by Gail Henderson Breakdown of academic impact, for papers by Suzanne Greiner Breakdown of academic impact, for papers by Steven J. Werden Breakdown of academic impact, for papers by Karen J. Scott Breakdown of academic impact, for papers by Elena A. Kashentseva Breakdown of academic impact, for papers by Katherine L. Molnar-Kimber Breakdown of academic impact, for papers by Louisa S. Chard Breakdown of academic impact, for papers by James C. Neil
Rankless by CCL
2026